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ABSTRACT Aggregation of cell surface receptors by multivalent ligand can trigger a variety of cellular responses. A
well-studied receptor that responds to aggregation is the high affinity receptor for IgE (FcRI), which is responsible for
initiating allergic reactions. To quantify antigen-induced aggregation of IgE-FcRI complexes, we have developed a method
based on multiparameter flow cytometry to monitor both occupancy of surface IgE combining sites and association of antigen
with the cell surface. The number of bound IgE combining sites in excess of the number of bound antigens, the number of
bridges between receptors, provides a quantitative measure of IgE-FcRI aggregation. We demonstrate our method by using
it to study the equilibrium binding of a haptenated fluorescent protein, 2,4-dinitrophenol-coupled B-phycoerythrin (DNP25-
PE), to fluorescein isothiocyanate-labeled anti-DNP IgE on the surface of rat basophilic leukemia cells. The results, which we
analyze with the aid of a mathematical model, indicate how IgE-FcRI aggregation depends on the total concentrations of
DNP25-PE and surface IgE. As expected, we find that maximal aggregation occurs at an optimal antigen concentration. We
also find that aggregation varies qualitatively with the total concentration of surface IgE as predicted by an earlier theoretical
analysis.
INTRODUCTION
Aggregation of cell surface receptors is a common mecha-
nism involved in signal transduction across a cell membrane
(Metzger, 1992). This mechanism is used, for example, by
receptors that are intrinsic protein tyrosine kinases (Pazin
and Williams, 1992; Fry et al., 1993), such as the epidermal
growth factor receptor (Schreiber et al., 1982) and the
platelet derived growth factor receptor (Heldin et al., 1989),
and by multichain immune recognition receptors (Keegan
and Paul, 1992), such as the high affinity receptor for IgE
(FcRI) (Holowka and Baird, 1996) and the B-cell receptor
(Kaye et al., 1983; Kaye and Janeway, 1984; Cambier and
Ransom, 1987). For many of these receptors, early steps in
the initiation of a signal are similar: multivalent interactions
with a ligand lead to the aggregation of receptors and
enhanced phosphorylation of tyrosines, which can be rec-
ognized by cytoplasmic regulatory molecules. The FcRI
receptor, for example, is triggered when IgE-FcRI com-
plexes are aggregated by multivalent antigen. Aggregation
of FcRI, which is constitutively associated with the protein
tyrosine kinase Lyn (Eiseman and Bolen, 1992), then leads
to a series of events, which include recruitment of additional
Lyn kinases (El-Hillal et al., 1997; Wofsy et al., 1997).
Signals generated by aggregation of FcRI, which can be
negative or positive, depend on various properties of the
aggregate structures that are formed on the cell surface.
These properties include the overall number of receptors in
aggregates on the cell surface, the size of aggregates (Few-
trell and Metzger, 1980; MacGlashan et al., 1983), the
spacing of receptors in aggregates (Kane et al., 1986), and
the time that individual receptors spend in aggregates (To-
rigoe et al., 1998). For example, it has been observed that
IgE dimers are less effective than larger IgE oligomers at
stimulating cellular responses (Fewtrell and Metzger, 1980)
and that cellular responses are inhibited when an optimal
degree of aggregation is exceeded (Becker et al., 1973;
Menon et al., 1984; Seagrave and Oliver, 1990). Depen-
dency of cellular responses on properties of receptor aggre-
gates also has been observed for related receptors, such as
the B-cell receptor (Dintzis et al., 1976, 1983) and T-cell
receptor (Sloan-Lancaster et al., 1994; Madrenas et al.,
1995; Lyons et al., 1996; Neumeister Kersh et al., 1998).
Because properties of ligand-induced receptor aggregates
influence the signals that these aggregates generate, signif-
icant effort has been devoted to quantitative analysis of
interactions between multivalent ligands and cell surface
receptors, particularly in work with FcRI (Goldstein, 1988;
Goldstein and Wofsy, 1994). A goal of these studies has
been to measure or predict the number of receptors in
aggregates on the cell surface so that this quantity then can
be compared and correlated with cellular responses (Dembo
et al., 1978, 1979; Dembo and Goldstein, 1980; MacGlas-
han and Lichtenstein, 1983; MacGlashan et al., 1985). The
number of receptors in aggregates is related to the number
of receptor sites in aggregates, which in turn is related to the
number of bound receptor sites in excess of the number of
bound ligands. This difference, which can be interpreted as
the number of receptor pairs in clusters (Perelson, 1981), is
zero when ligand binding is monovalent and positive when
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ligand binding is multivalent because each bound ligand
must engage at least one receptor site. Thus, we can quan-
tify receptor aggregation if we can measure ligand and
receptor site binding.
One method to determine both the number of ligands
bound to receptors and the occupancy of receptor sites
involves differentially labeled monovalent and multivalent
ligands. This method has been used in experiments with
chemically cross-linked oligomers of IgE. For example, by
incubating rat basophilic leukemia (RBL) cells, which ex-
press FcRI, with 125I-labeled dimers of IgE and then by
adding 131I-labeled IgE to assay the number of Fc receptor
sites left unbound by IgE dimers, one can determine the
number of Fc receptor sites in dimer-induced aggregates
(Segal et al., 1977). This method works well with IgE
oligomers, because IgE-FcRI complexes are long lived
(Kulczycki and Metzger, 1974; Sterk and Ishizaka, 1982).
On the time scale of an experiment, the equilibrium between
oligomeric IgE and FcRI is undisturbed by monomeric
IgE. However, the method is difficult to apply when recep-
tor sites have low affinity for sites on the multivalent ligand,
as in a typical physiological situation, because introduction
of monovalent ligand can now rapidly influence binding of
the multivalent ligand to receptors.
Here, we develop a method that can be used to measure
simultaneously the amount of multivalent ligand bound to
receptors and the occupancy of receptor sites without the
complication of introducing a monovalent ligand. The
method combines approaches previously used to measure
the amount of ligand bound to receptors (Seagrave et al.,
1987) and the occupancy of receptor sites (Erickson et al.,
1986). To demonstrate the method, we study the equilib-
rium binding of haptenated phycoerythrin to anti-hapten
IgE, which is labeled with fluorescein isothiocyanate
(FITC). By using two-color flow cytometry to measure
fluorescence of phycoerythrin and FITC, we are able to
estimate the amount of antigen on the surface of RBL cells
and the occupancy of surface IgE combining sites. These
measurements also allow us to estimate the number of
FcRI pairs in antigen-induced clusters, i.e., the extent of
receptor cross-linking.
Estimates of cross-linking are refined with the aid of a
mathematical model, which we fit to data. The data are
consistent with a model that accounts for cooperative ef-
fects, which arise, at least in part, for steric reasons. The
model, which reduces to an equivalent site model (Perelson,
1981, 1984; Macken and Perelson, 1985; Lauffenburger and
Linderman, 1993; Sulzer and Perelson, 1996) in the absence
of cooperative effects, allows us not only to refine our
estimates of cross-linking but also to determine equilibrium
binding parameters. Furthermore, the development of this
model, together with the ability to test its predictions against
experimental measurements of both ligand binding and re-
ceptor site binding, provide new insights into methods for
quantifying multivalent ligand-receptor interactions.
MODEL
To aid in analysis of experimental data, we develop a model
for equilibrium binding of 2,4-dinitrophenol-coupled B-
phycoerythrin (DNP25-PE) to anti-DNP IgE-FcRI com-
plexes on RBL cells. In this model, we treat IgE-FcRI as a
bivalent cell surface receptor: each antibody combining site
in an IgE-FcRI complex represents one of two potential
binding sites per receptor for the ligand, DNP25-PE.
Reaction scheme
The model is based on the reaction scheme shown in Fig. 1
A in which ligands bind and aggregate receptor sites through
a series of reversible reactions. The initial reaction involves
the binding of solution-phase ligand to a receptor site, and
each subsequent reaction involves the addition of a receptor
site to a ligand-receptor complex (Fig. 1 B). In this scheme,
ligand-receptor complexes form without intramolecular re-
arrangement reactions, i.e., without either ring or network
formation reactions (Perelson, 1984; Macken and Perelson,
1985). If these reactions were significant, then the scheme
in Fig. 1 A would have to be modified.
As indicated, the model is developed in terms of ligand
states. Thus, variables in the model include the concentra-
tion of ligand in solution, which is denoted as L0, the surface
density of ligand that is bound to i receptor sites, which is
denoted as Li, and the surface density of free receptor sites,
which is denoted as S. Related variables include the total
concentration of ligand, which is denoted as LT, and the
total surface density of receptor sites, which is denoted as
ST.
Equilibria
To characterize the equilibria for the reactions in Fig. 1 A,
we write
i 1Li1 n iKiSLi for i 0, . . . , n 1 (1)
FIGURE 1 Reaction scheme. (A) Ligands bind receptor sites through a
series of reversible reactions. L0, L1, L2, and S indicate, respectively, a
ligand in solution, a ligand bound to one receptor site, a ligand bound to
two receptor sites, and a free receptor site. (B) A sequence of possible
reactions is illustrated.
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in which n is the chemical valence of the ligand (i.e., the
number of DNP groups per PE molecule) and each Ki is an
equilibrium constant. The equilibrium constant K0 charac-
terizes the affinity of a receptor site for a ligand site (i.e., a
DNP group) when the ligand is in solution, and the cross-
linking equilibrium constant Ki (i  1) characterizes the
affinity of a receptor site for a ligand site when the ligand is
bound to i receptor sites (Dembo and Goldstein, 1978;
Perelson, 1981). If K1 through Kn1 are identical, Eq. 1
reduces to an equivalent site model (Perelson, 1981, 1984;
Macken and Perelson, 1985; Lauffenburger and Linderman,
1993; Sulzer and Perelson, 1996).
Cooperativity
Sites on the ligand DNP25-PE are chemically identical: each
is a DNP group. Thus, the equilibrium constants in Eq. 1 are
related, although K1 through Kn1 need not be identical.
Differences among these equilibrium constants indicate
functional nonequivalence of ligand sites (i.e., cooperativ-
ity), which can arise for a variety of physical reasons
(Perelson, 1984). Sites on DNP25-PE are likely to be func-
tionally nonequivalent, at least in part, for steric reasons.
The crystal structure of B-phycoerythrin (Ficner et al.,
1992; Ficner and Huber, 1993) indicates that this molecule
is cylindrical with a height of 6 nm and a diameter of 11 nm.
Thus, the exposed surface area of DNP25-PE is200 square
nm, which is insufficient to allow binding of more than a
few DNP sites because the area covered by a bound anti-
body Fab arm is at least 30 square nm (Poljak et al., 1973;
Padlan, 1994).
To account for functional nonequivalence of sites on
DNP25-PE, we introduce a cooperativity function (i) to
relate the cross-linking equilibrium constants K1 through
Kn1 (Cantor and Schimmel, 1980):
Ki e
(i)K1 for i 1, . . . , n 1 (2)
in which (1)  0. The functional form of (i) is chosen to
indicate how cooperative effects are expected to influence
binding as a function of ligand site occupancy. If (i)  0
for all i, sites are functionally equivalent and K1 through
Kn1 are identical. However, for steric reasons, we can
expect the value of the cross-linking equilibrium constant Ki
to approach zero as i approaches the effective valence of
DNP25-PE, which we expect to be much less than the
chemical valence n. This suggests that we should specify
(i) as an increasing function of i. The simplest such form
for (i), with the required property that (1)  0, is a(i 
1), in which a is a positive constant.
Conservation
Because experiments are performed under conditions that
inhibit recycling of FcRI, we treat the total numbers of
ligands and receptor sites as conserved quantities. Conser-
vation of ligand can be expressed as
LT L0 C 
i1
n
Li (3)
in which LT is the total concentration of ligand and C is a
factor that converts surface densities to concentrations. This
factor is the cell concentration, expressed in the same units
as LT, if each surface density Li is expressed in units of
ligand molecules per cell. Conservation of receptor sites can
be expressed as
ST S 
i1
n
iLi (4)
in which ST is the total surface density of receptor sites,
which is twice the total surface density of receptors.
Cross-linking
Ligand-induced aggregation of receptors is quantified by
the number of cross-links on the cell surface. A cross-link is
defined as follows (Perelson, 1981). In the absence of
intramolecular rearrangement reactions, as in the scheme of
Fig. 1 A, a ligand bound at i sites is attached to i receptors.
Thus, a ligand bound at two sites, as depicted in Fig. 1 B,
forms a single cross-link, i.e., a cluster of two receptors. If
we generalize this concept of a cross-link, then a ligand
bound at i sites forms i  1 cross-links, i.e., i  1 clusters
of receptor pairs. Consequently, in the absence of intramo-
lecular rearrangement reactions, the number of cross-links is
given by ¥i1
n (i  1)Li, which is equivalent to the number
of bound receptor sites (¥i1
n iLi) in excess of the number of
bound ligands (¥i1
n Li).
MATERIALS AND METHODS
Reagents
Mouse monoclonal anti-DNP IgE was isolated from hybridoma H1 26.82
(Liu et al., 1980) by affinity purification (Holowka and Metzger, 1982).
Final steps in the purification process included ion exchange chromatog-
raphy to remove bound DNP-glycine, then gel filtration to separate mo-
nomeric IgE from small amounts of IgE aggregates. Fluorescently labeled
IgE (FITC-IgE) was prepared by attaching fluorescein-5-isothiocyanate
(Molecular Probes, Eugene, OR) to IgE (Erickson et al., 1986). The
fluorescent antigen DNP25-PE, which is composed of 2,4-dinitrophenol
(DNP) and B-phycoerythrin (PE), was custom synthesized by Molecular
Probes. The molar ratio of DNP to PE is 25:1. The molecular weight of
DNP25-PE is 250,000.
Cells
RBL-2H3 cells (Barsumian et al., 1981) were grown adherent in 75 cm2
flasks. Cell cultures, which were used typically 5 days after passage, were
maintained at 37°C and 5% CO2. Culture media consisted of MEM 1X
with Earle’s salts without glutamine (Gibco BRL), 20% fetal bovine serum
(HyClone, Logan, UT), 1% v/v L-glutamine, 1% v/v penicillin, and 1% v/v
streptomycin (Gibco BRL). To harvest cells, we rinsed and then incubated
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the cells for 5 minutes at 37°C with trypsin-EDTA (Gibco BRL). Cells
harvested for experiments were washed and resuspended in buffered salt
solution (pH 7.7), which was freshly passed through a 0.22-c filter.
Buffered salt solution (BSS) consisted of 135 mM NaCl, 5 mM KCL, 1
mM MgCl2, 1.8 mM CaCl2, 5.6 mM glucose, 0.1% gelatin, and 20 mM
Hepes. Cell suspensions in buffered salt solution were supplemented with
10 mM sodium azide and 10 mM 2-deoxy-D-glucose (Sigma, St. Louis,
MO) to inhibit receptor recycling and cellular degranulation during binding
experiments. To sensitize cells to DNP, we incubated cells overnight while
cells were still in culture with excess (10 g) anti-DNP FITC-IgE. Sensi-
tized cells were exposed to FITC-IgE for at least 12 h prior to harvesting.
Flow cytometric binding assays
In each binding experiment, we incubated a suspension of sensitized cells
at a density of 2.5 105, 106, or 4 106 cells/ml, with DNP25-PE at room
temperature. The concentration of DNP25-PE varied from 0.0001 to 100
g/ml. After cells were incubated with DNP25-PE for at least 90 min, we
used a Becton Dickinson FACScan flow cytometer, which was controlled
with Cell Quest software, to collect histograms of FITC and PE fluores-
cence. We determined that 90 min was sufficient for binding to reach
equilibrium at the relevant cell and ligand concentrations, because neither
FITC nor PE fluorescence varied significantly as we varied the incubation
time from 1 to 2 hours. Flow cytometric data were recorded as the mean
FITC fluorescence (520 nm) of the cell suspension, FL1, and as the mean
PE fluorescence (550 nm) of the cell suspension, FL2. To correct for
nonspecific binding of DNP25-PE to cells, we performed a control exper-
iment in which cells lacked surface IgE. The difference between FL2 and
the mean PE fluorescence for the control sample, 	FL2, indicates the PE
fluorescence due only to specific binding. To relate PE fluorescence to the
surface density of DNP25-PE, measurements of 	FL2 were calibrated by
using microspheres embedded with a known amount of B-phycoerythrin
(Flow Cytometry Standards Corporation, San Juan, PR).
Data analysis
Relating measurements of fluorescence to binding
The fraction of surface IgE combining sites that are bound to DNP25-PE,
which we denote as 	, is related to variables in the model and, as
established in earlier work (Erickson et al., 1986), to quenching of FITC-
IgE fluorescence:
	  1 S/ST 
i1
n
iLi/ST
 FL1max FL1/FL1max FL1min
(5)
in which FL1 is FITC fluorescence, FL1max is FL1 when all surface IgE
combining sites are free (	  0), and FL1min is FL1 when all surface IgE
combining sites are bound (	  1). In Eq. 5, the number of bound IgE
combining sites ST S is normalized by the total number of IgE combining
sites ST. Below, we also use ST to normalize quantities that characterize
DNP25-PE binding and cross-linking, because neither the number of bound
DNP25-PE molecules nor the number of cross-links can be greater than the
total number of IgE combining sites.
The ratio of cell-bound DNP25-PE to surface IgE combining sites,
which we denote as 
, is related to variables in the model and, as
established in earlier work (Seagrave et al., 1987), to measurements of PE
fluorescence:

  
i1
n
Li/ST 	FL2/	FL2max (6)
in which 	FL2 is PE fluorescence due to specific binding of DNP25-PE to
surface IgE and 	FL2max is 	FL2 when DNP25-PE binding is saturated,
i.e., when each IgE combining site is bound to one molecule of DNP25-PE
(
  1).
Based on our earlier definition of a cross-link, the number of cross-links
per IgE combining site, which we denote as , is related to 	 and 
 as
follows:
  
i1
n
i 1Li/ST 
i1
n
iLi/ST 
i1
n
Li/ST 	 
 (7)
In the absence of intramolecular rearrangement reactions,  indicates
the normalized number of clustered IgE-FcRI pairs. In the presence of
these reactions,  is still related to cross-linking; however, in this case, 
is no longer directly proportional to the number of cross-links.
Estimating parameters by fitting the model to data
Three sets of data were used to determine best-fit values for K0, K1, ST, and
a, where a is a parameter in the specified cooperativity function (i). We
considered various one-parameter functional forms for (i), including
(i)  a(i  1). Each data set consisted of measurements of FITC
fluorescence (FL1) and PE fluorescence (	FL2) for a series of ligand
concentrations. These measurements were taken at one of three cell den-
sities: 2.5 105, 106, or 4 106 cells/ml. Because data sets were collected
with different instrument settings, it was necessary to determine best-fit
scaling factors (FL1min, FL1max, and 	FL2max) for each set of FL1 and
	FL2 measurements.
Best-fit parameter values were determined by using the FORTRAN
subroutine DNLS1 from the SLATEC Common Mathematical Library
(http://www.netlib.org/slatec), which implements a modified Levenberg-
Marquardt algorithm for solving nonlinear least-squares problems.
Solving the model equations
Equilibrium states are calculated by solving the model equations, which is
aided by combining Eqs. 1–4. By using Eq. 1 to express each Li as a
function of S and L0, by using Eq. 2 to relate K1 through Kn1, and by using
Eq. 3 to express L0 as a function of S, we can rewrite Eq. 4 to obtain
1 S/ST
K0LTi1n ii
1 K0CSTi1n i (8)
in which
i niexp 
j0
i1
jK1STi1S/STi (9)
Here, we adopt the convention that (0)  0. Cooperative effects are
included entirely in the exponential term of Eq. 9. If this term reduces to
1, Eqs. 8 and 9 reduce to an equivalent site model.
When values for the parameters (n, C, LT, ST, K0, and K1) and a
functional form for the cooperativity function (i) are specified, Eq. 8 is a
nonlinear equation involving a single unknown: the fraction of free recep-
tor sites S/ST. To determine the fraction of free receptor sites at equilib-
rium, we solve this equation by using the method of bisection (Press et al.,
1992). Once S/ST is known, other states at equilibrium can be determined
by using the relations L0/LT  1/[1  K0CST¥i1
n (i)] and Li/ST 
(K0LT)(L0/LT)(i), which are derived from Eqs. 1–3.
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RESULTS
We use multiparameter flow cytometry to study the equi-
librium binding of a multivalent ligand to a cell surface
receptor. The ligand, DNP25-PE, is haptenated phyco-
erythrin (PE): each molecule of PE is coupled to an average
of 25 DNP molecules. The receptor for this ligand is FITC-
labeled anti-DNP IgE that is bound to FcRI on the surface
of RBL cells. Below, we first present qualitative features of
DNP25-PE binding to surface IgE, and we then illustrate
how measurements of PE and FITC fluorescence can be
used to quantify antigen-induced aggregation of IgE-FcRI
complexes. The methods developed here allow us to deter-
mine how equilibrium cross-linking varies quantitatively
with the total concentrations of ligand and receptor.
Qualitative features of antigen binding to
surface IgE
In our experiments, DNP25-PE at various concentrations is
added to suspensions of RBL cells that have been sensitized
with FITC-IgE. Then, after equilibrium is reached, PE and
FITC fluorescence are measured simultaneously in a flow
cytometer. Fluorescence measurements for a series of ex-
periments are shown in Fig. 2. As the concentration of
DNP25-PE increases, FITC fluorescence (FL1) decreases
and PE fluorescence (	FL2) increases. A decrease in FITC
fluorescence indicates an increase in the occupancy of IgE
combining sites (Erickson et al., 1986), and an increase in
PE fluorescence indicates an increase in association of
DNP25-PE with the cell surface (Seagrave et al., 1987).
Receptor binding saturates before ligand binding
As can be seen in Fig. 2, receptor sites saturate (i.e., FL1
reaches a lower plateau) at a ligand concentration of 0.1
g/ml, whereas ligand binding, as measured by 	FL2, fails
to reach an obvious plateau even at ligand concentrations
greater than 10 g/ml. This effect cannot be explained by
nonspecific binding of ligand to cells, which was assayed in
control experiments, because 	FL2 represents the PE fluo-
rescence due only to specific binding. We expect that 	FL2
continues to rise after FL1 reaches a plateau for the follow-
ing reason. When FL1 first reaches a plateau, ligand binding
is multivalent. Then, as the ligand concentration increases,
the multiplicity of ligand binding decreases, which allows
more ligand to bind to the cell surface. As a result, 	FL2
increases. This explanation is consistent with the binding
parameters that we later determine.
Ligand binding approaches saturation
At ligand concentrations greater than 20 g/ml, measure-
ments of PE fluorescence are unreliable due to light scatter.
Thus, we are unable to measure PE fluorescence at satura-
tion (i.e., we are unable to measure 	FL2max) as is required
to directly relate measurements of PE fluorescence to the
extent of ligand binding (Eq. 6). Nevertheless, by using
microspheres embedded with a known amount of PE to
calibrate measurements of 	FL2, we are able to estimate the
extent of ligand binding. The calibration results indicate that
the highest recorded value of 	FL2 in Fig. 2 (1380) corre-
sponds to 9  105 PE molecules per cell and at least the
same number of receptor sites per cell (each bound ligand
engages at least one receptor site). Thus, ligand binding
approaches saturation in the experiments of Fig. 2 because
RBL cells only express 300,000 to 600,000 FcRI receptors
per cell (Erickson et al., 1987). Based on this expected
number of FcRI receptors per cell, we can estimate that the
highest recorded value of 	FL2 is within at least 75% of
	FL2max because the minimum number of receptor sites per
cell indicated by bead calibration (9  105) is 75% of the
maximum number of surface IgE combining sites per RBL
cell (1.2  106). As we will see later, model-based analysis
indicates that ligand binding actually approaches 90% sat-
uration in the experiments of Fig. 2.
Quantifying antigen-induced aggregation of
surface IgE sites
We quantify receptor aggregation by determining the num-
ber of bound receptor sites in excess of the number of bound
ligands. To determine this quantity, which we interpret as
the number of cross-links, we must measure or estimate the
scaling factors in Eqs. 5–7 (FL1min, FL1max, and 	FL2max)
and then use these equations to relate measurements of
fluorescence (FL1 and 	FL2) to quantities that characterize
ligand and receptor binding (	, 
, and ).
Fluorescence measurements directly indicate a lower
bound on cross-linking
The highest recorded value of 	FL2 represents a lower
bound on 	FL2max. By using this lower bound, we can
FIGURE 2 Flow cytometric measurements of PE and FITC fluorescence
that monitor equilibrium binding of DNP25-PE to FITC-IgE on the surface
of RBL cells. The cell density is 106 cells/ml.
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place an upper bound on the extent of ligand binding and a
lower bound on the extent of cross-linking, as can be seen
by inspecting Eqs. 6 and 7. In Eq. 6, the number of bound
ligands per receptor site 
 is defined as 	FL2/	FL2max.
Thus, an underestimate of 	FL2max leads to an overestimate
of 
. In Eq. 7, the number of cross-links per receptor site 
is defined as 	  
. Thus, an overestimate of 
 leads to an
underestimate of .
In Fig. 3, we show how the fluorescence measurements of
Fig. 2 are related to biologically meaningful quantities. In
Fig. 3 A, we plot receptor site occupancy 	, which is
calculated by using Eq. 5, as a function of ligand concen-
tration. The scaling factors FL1min and FL1max, which ap-
pear in Eq. 5, are readily determined from the fluorescence
data (Fig. 2). In Fig. 3 B, we plot the extent of ligand
binding 
, which is calculated by using Eq. 6, as a function
of ligand concentration. The values of 
 were calculated by
using the highest recorded value of 	FL2 for 	FL2max in
Eq. 6. Because we have determined only that this value is
within 75% of 	FL2max (on the basis of our bead calibration
results), values of 
 are uncertain to the extent indicated by
the error bars. However, as illustrated, the fluorescence data
directly indicate an upper bound on ligand binding. In Fig.
3 C, we plot the extent of cross-linking , which is calcu-
lated by using Eq. 7, as a function of ligand concentration.
As illustrated, an upper bound on 
 translates to a lower
bound on . Note that the increasing portion of the cross-
linking curve is insensitive to the estimated uncertainty in
	FL2max.
Model-based analysis of fluorescence data yields refined
estimates of receptor site occupancy, ligand binding, and
cross-linking
To aid in the analysis of fluorescence data, we developed a
model for ligand-receptor binding (Eqs. 1–4). We simulta-
neously fit this model to three data sets, one of which is that
shown in Fig. 2. Each data set was collected at a different
cell density. The following best-fit parameter values, which
apply for all three data sets, were determined: K0  4.4 
108 M1, K1ST  13, and ST  9.6  10
5 sites/cell. The
fitting procedure also allowed us to specify a  0.43 for the
cooperativity function (i)  a(i  1). We considered a
variety of one-parameter functional forms for (i), but
functions consistent with the data indicated essentially the
same values for the cross-linking equilibrium constants K1
through Kn1. In addition to these parameter values, we also
determined for each data set best-fit values for the scaling
factors FL1min, FL1max, and 	FL2max. For example, we
determined that 	FL2max  1500 for the data set of Fig. 2,
which indicates that ligand binding in these experiments
reached 90% saturation (1380/1500).
The extent to which the model fits the data is illustrated
in Fig. 4. Both the fraction of bound receptor sites and the
number of bound ligands per receptor site are plotted as a
function of ligand concentration. The points are derived
from the fluorescence data of Fig. 2, Eqs. 5 and 6, and the
best-fit scaling factors. These plots meet two expectations.
First, the fraction of bound receptor sites 	 is greater than or
equal to the number of bound ligands per receptor site 
.
FIGURE 3 Equilibrium binding characterized by measurements of PE
and FITC fluorescence. Fluorescence measurements directly indicate (A)
the fraction of receptor sites bound 	, (B) an upper bound on the number
of bound ligands per receptor site 
, and (C) a lower bound on the number
of cross-links per receptor site . The points were derived from the
fluorescence data in Fig. 2 by using Eqs. 5–7 and the scaling factors:
FL1min  184, the lowest recorded value of FL1, FL1max  450, the
highest recorded value of FL1, and 	FL2max  1380, the highest recorded
value of 	FL2. The error bars in B and C indicate the uncertainty in 
 and
 if the highest recorded value of 	FL2 (1380) is within 75% of the actual
	FL2max, as suggested by bead calibration. The small solid points at the
end of error bars are based on 	FL2max  1380/0.75. The cell density is
106 cells/ml.
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This result is expected because each bound ligand must
engage at least one receptor site. Thus, 	 must be greater
than 
 when ligand binding is multivalent, and 	 must equal

 when ligand binding is monovalent. Second, 	 and 

converge at high ligand concentrations, which indicates that
ligand binding is predominantly monovalent at these con-
centrations. The quality of the fit illustrated in Fig. 4 is
typical of the fits for the other two data sets.
The best-fit parameter values are consistent with inde-
pendent data. The number of IgE combining sites per cell,
9.6  105, is consistent with our bead calibration results,
which indicate 9  105 sites per cell, and with the number
of FcRI receptors (300,000 to 600,000 per cell) that are
expressed on RBL cells (Erickson et al., 1987). The esti-
mated affinity of anti-DNP IgE for DNP on haptenated PE,
4.4 108 M1, is comparable with the affinity of anti-DNP
IgE for DNP on haptenated bovine serum albumin, 8.5 
108 M1 (Xu et al., 1998). As expected, for steric reasons,
the cooperativity function (i)  0.43(i  1) is an increas-
ing function of ligand site occupancy i. Also, as is consistent
with the structures of Fab and PE, theoretical values for the
ratio 	/
, which indicates the number of bound receptor
sites per bound ligand molecule, are much less than the
chemical valence of DNP25-PE. For example, 	/

 4 at 0.1
g/ml in Fig. 4 is where the cross-linking curve peaks (Fig.
5). Cross-linking is indicated by the vertical distance be-
tween the two curves in Fig. 4 because   	  
 (Eq. 7).
The binding curves in Fig. 4, which are derived from our
model-based analysis, can be compared with those in Fig. 3,
which are derived directly from the fluorescence data. The
two curves for receptor site binding are identical as can be
seen by comparing Fig. 3 A with the corresponding plot in
Fig. 4. The two curves for ligand binding also are similar.
The binding curve in Fig. 4 falls within the range indicated
in Fig. 3 B for ligand binding. In fact, this curve closely
matches the upper bound on ligand binding indicated in Fig.
3 B. This suggests that our estimated upper bound on ligand
binding and the resulting lower bound on cross-linking are
tight and that the error bars shown in Fig. 3 overestimate the
uncertainty in measurement of these quantities. The analy-
sis-refined cross-linking curve that corresponds to Fig. 3 C
is shown in Fig. 5.
Dependence of cross-linking on ligand and
receptor concentration
In Fig. 5, we plot the extent of cross-linking  as a function
of ligand concentration for three cell densities. The points
are derived from fluorescence measurements by using Eqs.
5–7 and best-fit scaling factors. Each curve indicates how
cross-linking varies as a function of ligand concentration at
a particular cell density or equivalently a particular receptor
or receptor site concentration. Each of these cross-linking
curves is bell shaped, as expected. Cross-linking increases
with ligand concentration up to an optimal ligand concen-
tration and then decreases as monovalent binding, because
of excess ligand, begins to predominate.
The results shown in Fig. 5 indicate that cross-linking is
influenced by the cell density. Three features are discern-
ible. First, the location of the increasing portion of the
cross-linking curve depends on the cell density. This portion
FIGURE 4 Comparison of best-fit theoretical binding curves with scaled
data. The fraction of bound receptor sites 	 (circles) and number of bound
ligands per receptor site 
 (squares) are plotted as a function of ligand
concentration. The points were derived from the fluorescence data in Fig.
2 by using Eqs. 5 and 6, FL1min  184, FL1max  450, and 	FL2max 
1500. The broken and solid lines indicate the theoretical binding curves,
which are based on the model equations (Eqs. 1–4), Eqs. 5 and 6, n  25,
ST  9.6  10
5 sites/cell, K0  4.4  10
8 M1, K1ST  13, and (i) 
0.43 (i  1). The cell density is 106 cells/ml.
FIGURE 5 Best-fit estimates of cross-linking as a function of ligand
concentration for three cell densities. The number of cross-links per recep-
tor site  is plotted as a function of ligand concentration for 2.5  105
cells/ml (triangles), 106 cells/ml (circles), and 4  106 cells/ml (squares).
The points were derived from fluorescence data and best-fit scaling factors.
For example, the points indicated by circles were derived from the fluo-
rescence data in Fig. 2 by using Eqs. 5–7, FL1min  184, FL1max  450,
and 	FL2max  1500. The lines indicate the theoretical binding curves,
which are based on the model equations (Eqs. 1–4), Eq. 7, n  25, ST 
9.6  105 sites/cell, K0  4.4  10
8 M1, K1ST  13, and (i)  0.43
(i  1).
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of the curve, which corresponds to the regime where recep-
tor sites are not saturated, shifts to the right as the cell
density increases. Thus, at a fixed ligand concentration,
cross-linking decreases as the cell density increases if re-
ceptor site binding is below saturation. Second, the peak of
the cross-linking curve is independent of cell density, i.e.,
each curve has the same maximum height. Third, the loca-
tion of the decreasing portion of the cross-linking curve,
which corresponds to the regime where receptor sites are
saturated, tends not to depend on the cell density. As can be
seen, the three curves coincide at ligand concentrations
greater than 1 g/ml. These qualitative features of cross-
linking curves were predicted in an earlier theoretical anal-
ysis (Sulzer and Perelson, 1996).
DISCUSSION
In many antigen, hormone, and cytokine receptor systems,
signal transduction is initiated by aggregation of cell surface
receptors (Metzger, 1992). However, even in the well-stud-
ied FcRI system, the features of ligand-receptor binding
that are critical for signaling have yet to be fully character-
ized, especially for cases in which the ligand has more than
two binding sites. Here, we have developed and applied a
flow cytometric method to monitor receptor site occupancy
(Figs. 3 A and 4), ligand binding (Figs. 3 B and 4), and
cross-linking (Figs. 3 C and 5). This study, like the recent
work of Xu et al. (1998), represents an attempt to quantify
the interactions of a multivalent antigen with IgE-FcRI.
The method that we have developed to quantify FcRI
aggregation is significant for several reasons. First, the
antigen is a haptenated protein (DNP25-PE) that resembles a
physiological allergen. Like an allergen, it elicits strong
cellular responses (Seagrave et al., 1987). This is in contrast
to bivalent haptens (Siraganian et al., 1975; Kane et al.,
1986; Posner et al., 1995a). Also like an allergen, DNP25-PE
cross-links FcRI via antigen-antibody reactions. This is in
contrast to oligomers of IgE; the kinetics of IgE binding to
FcRI differ significantly from typical antigen-antibody ki-
netics (Kulczycki and Metzger, 1974; Sterk and Ishizaka,
1982). Second, the method allows us to characterize reac-
tions on the cell surface without disturbing these reactions.
This is in contrast to another flow cytometric method that
recently has been developed to study multivalent ligand-
receptor binding (Woodard et al., 1995). In this method,
which we discuss later, a labeled monovalent ligand is used
to determine the number of receptor sites that are bound by
a differentially labeled multivalent ligand. Third, our
method can be applied not only in equilibrium binding
studies, as we have demonstrated here, but also in kinetic
studies (Posner et al., 1998). Kinetic binding studies may be
important for understanding the temporal properties of
FcRI aggregates that influence signaling (MacGlashan et
al., 1985; Torigoe et al., 1998).
We quantify receptor aggregation by determining two
quantities: the number of bound receptor sites and the
number of bound ligands. These quantities reveal informa-
tion about the state of receptor aggregation. For example, if
the number of bound ligands equals the number of bound
receptor sites, then each ligand is bound to a single receptor
site and no receptors are aggregated. In the absence of
intramolecular rearrangement reactions, the number of
bound receptor sites in excess of the number of bound
ligands can be interpreted as the number of cross-links, i.e.,
the number of clustered receptor pairs (Perelson, 1981). We
assume that this interpretation is valid here, i.e., we say that
a cross-link is formed each time two receptor sites are
joined. However, our use of this assumption does not rep-
resent a limitation of the method because cross-linking can
be determined more directly if bispecific chimeric IgE is
available. In experiments with this reagent, receptor aggre-
gation is equivalent to receptor site aggregation, which is
indicated by the number of bound receptor sites in excess of
the number of bound ligands.
One approach that has been used to quantify FcRI ag-
gregation involves oligomers of IgE (Segal et al., 1977).
The number of bound oligomers is determined by radiola-
beling. Monomeric IgE labeled with a different isotope is
then used to determine the number of free FcRI receptors.
Because dissociation of IgE from FcRI is slow (Kulczycki
and Metzger, 1974; Sterk and Ishizaka, 1982), it is possible
to add oligomeric IgE, reach equilibrium, and then add
excess monomeric IgE to fill empty Fc sites without dis-
turbing oligomer binding on the time scale of the experi-
ment. Although oligomers of IgE are useful tools for study-
ing receptor aggregation and subsequent cellular responses
in this system, they have a number of limitations (Goldstein,
1988). Aggregates can be no larger than the number of
chemically cross-linked IgE molecules, so IgE oligomers
are unable to produce signals that depend on large receptor
aggregates. Binding of IgE to FcRI is slow, so it may be
difficult to separate the kinetics of oligomer binding from
the kinetics of the cellular response. Also, IgE oligomers
produce long-lived cross-links, and thus their effects may be
atypical because signaling events that require the continual
formation of new cross-links will not be observed.
Recently, Woodard et al. (1995) used a multivalent anti-
gen to aggregate B-cell receptors and then used a differen-
tially labeled monovalent antigen to count free receptor
sites. Two-color flow cytometry was used together with
FITC-DNP-L-papain, as a monovalent antigen, and TRITC-
DNP-pol or TRITC-DNP-dextran, as a multivalent antigen,
to determine the amount of monovalent antigen and the
amount of multivalent antigen bound to DNP-specific B
cells. Data obtained with this indirect method are difficult to
interpret because the reactions are reversible (the typical
dissociation rate constant for a bond between DNP and an
antibody combining site is between 0.1 and 0.001 s1).
Thus, on the time scale of these experiments, the binding of
multivalent antigen is disturbed when the monovalent anti-
gen is added to the system. In comparison, our method of
measurement does not require an additional monovalent
probe. Thus, it avoids the complications that arise when
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different ligands compete for the same receptor. However,
our approach requires that we label the receptors, which is
impossible if the receptor is unavailable in a secreted form
or cannot be reattached to the cell surface. The second
condition is not fulfilled for many receptors, and conse-
quently, an indirect method such as that used by Woodard et
al. (1995) is then required to measure aggregation.
Another approach used to study FcRI aggregation in-
volves symmetric bivalent ligands, which represent the sim-
plest type of ligand capable of aggregating receptors. Math-
ematical models have been developed for bivalent ligands
interacting with bivalent cell surface receptors (Dembo and
Goldstein, 1978; Perelson and DeLisi, 1980; Perelson,
1980; Wofsy and Goldstein, 1987; Posner et al., 1995b).
However, a major limitation of these ligands is their inabil-
ity to activate strong cellular responses. A variety of evi-
dence suggests that these ligands are poor activators of
cellular responses because they aggregate receptors pre-
dominantly in the form of stable cyclic dimers (Kane et al.,
1986; Schweitzer-Stenner et al., 1987; Erickson et al., 1991;
Posner et al., 1991; Posner et al., 1995a). Cyclic dimers, in
which two ligand molecules connect two IgE-FcRI com-
plexes to form a closed ring, prevent chain elongation and
limit the size of ligand-induced aggregates. With ligands of
larger valence, such as DNP25-PE, ring formation does not
necessarily prevent growth of receptor aggregates. Thus,
multivalent ligands are capable of cross-linking many IgE
molecules and typically initiate strong cellular responses.
When interacting with surface IgE, these ligands can form
chain-, ring-, tree-, and network-like structures, whereas
bivalent ligands can form only chain- and ring-like struc-
tures. This advantage of multivalent ligands is also a disad-
vantage, because a theory that describes the binding of
multivalent ligands to bivalent receptors has yet to be fully
developed. However, in a variety of related reaction systems
studied in polymer chemistry, it has been found that ignor-
ing the intramolecular reactions that form rings and net-
works leads to results that adequately characterize most
aggregates (Flory, 1953), except those that form rubber-like
materials. For these reasons, we have used a theory of
multivalent ligand-receptor interactions that accounts for
chain- and tree-like but not ring- and network-like aggregate
structures. The model based on this theory is consistent with
our binding data (Figs. 4 and 5).
In our efforts to estimate parameter values, we observed
that unique best-fit parameter values are difficult to deter-
mine. To address this problem, we used three independent
data sets, each collected at a different cell density and each
consisting of both FL1 and 	FL2 measurements. We obtain
different results if we fit only FL1 data, only 	FL2 data, or
only data at a single cell density (unpublished material).
This suggests that models of multivalent ligand-receptor
interactions should be tested with a global analysis of mul-
tiple data sets (Posner and Dembo 1994; Myszka et al.,
1998).
In summary, we have demonstrated a method by which
the number of cross-links can be determined when both the
number of receptor sites occupied and the number of ligands
bound per receptor site are measured simultaneously. With
this technique, we have confirmed that the equilibrium
cross-linking curve is bell shaped (Figs. 3 C and 5). The
results shown in Fig. 5 also confirm qualitative predictions
concerning the influence of cell density on the cross-linking
curve (Sulzer and Perelson, 1996). As predicted, we observe
that an increase in cell density shifts the increasing portion
of the cross-linking curve toward higher ligand concentra-
tions, that the maximum height of the cross-linking curve is
independent of cell density, and that the decreasing portion
of the cross-linking curve also is independent of cell den-
sity. Thus, the equivalent site model studied by Sulzer and
Perelson (1996) apparently can be used to predict the qual-
itative features of cross-linking curves for real ligands.
However, to obtain quantitative estimates of binding param-
eters and more accurate quantification of ligand-receptor
aggregation, it was important here to consider a more com-
plicated model that included negative cooperativity due to
steric effects. In conclusion, we have developed new theo-
retical and experimental tools for studying multivalent li-
gand-receptor binding.
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